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The critical role of medication adherence in the success of
boceprevir and telaprevir in clinical practice
Letters to the EditorTo the Editor:
The excitement about the new standard of care for the treatment
of chronic hepatitis C virus (HCV) infection is warranted given the
dramatically increased rates of sustained virologic response
achieved with the addition of boceprevir or telaprevir to pegylat-
ed interferon and ribavirin in clinical trials. However, the success
of these two new direct antiviral agents (DAAs) in the real world
will depend on the ability of patients to adhere to them. Higher
rates of psychiatric and substance use disorders and cognitive
impairment in persons with chronic HCV, as compared to the
general population, place them at risk for medication nonadher-
ence. A similar development in the complexity of therapeutics
occurred in the treatment of HIV infection in the late 1990s with
the introduction of HIV protease inhibitors which led to an inten-
sive focus on treatment adherence.
The focus on adherence in HCV treatment to date has largely
been on early treatment discontinuation and dose reduction
rather than missed doses/injections [1] yet data collected through
electronic monitoring indicate that patients do miss a signiﬁcant
number of doses of ribavirin and interferon [2]. The additional
pill burden and treatment toxicity that DAAs will add to the con-
siderable existing treatment burden will increase the adherence
challenge for patients.
Boceprevir and telaprevir must be taken three times daily
(TID), 7–9 h apart, with food. We know from research that as dos-
ing frequency increases, dose adherence decreases [3]. Five well-
designed studies report on both dose adherence (deﬁned as the
correct number of pills taken in an observed time period) as well
as dose interval adherence (deﬁned as the correct number of
doses taken within 2 h of the scheduled dose time) to TID regi-
mens as assessed by electronic monitoring (Table 1). Mean dose
adherence ranges from 66% to 89% in these studies and mean
dose interval adherence from 5% to 53%.
Adherence data from clinical trials of telaprevir have not been
reported. Clinical trial adherence data of boceprevir [9] suggestTable 1. Dose adherence rates and dose interval adherence rates in studies examin
Chronic Condition Treated [Ref.] Number of participant
TID Regimen
Heart Disease [4] 68
HIV [5] 59
Epilepsy [6] 36
Diabetes [7] 15
Heart Failure [8] 26
aOnly median reported.
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Open access under CC Bthat adherence is most crucial for treatment experienced
patients; in this group, SVR decreased when patients had less
than 60% dose interval adherence, a level that is higher than
the mean in all studies in Table 1. In a comparison of telaprevir
dosing every 12 h vs. every 8 h, comparable rates of SVR were
observed [10]. However, it is noteworthy that this sample did
not include any treatment experienced patients.
Since patients in clinical trials routinely have better adherence
than patients in clinical practice, and considering the complexity
of the new generation of HCV treatment with DAAs, we propose
that the systematic assessment of adherence be incorporated into
HCV treatment guidelines. In addition, electronic monitoring of
adherence should be standard in DAA clinical trials and the
adherence data from these trials, including the relationship
between missed dose adherence and resistance development,
should be reported.
Methods to improve missed dose adherence to TID bocepre-
vir and telaprevir warrants dedicated attention. Since these
medications are time-limited, different adherence strategies
may be needed than in the case of medications for chronic con-
ditions, such as HIV. To maximize the likelihood of beneﬁt for
patients who begin the new HCV treatment regimens, resources
should be devoted to patient pre-treatment assessment and
preparation, as well as on-treatment adherence monitoring
and support. Focus on adherence will not only contribute to
treatment efﬁcacy but also serve to minimize the development
of resistant strains of HCV. This is important both for the
individual and for the general public health, due to the risk of
transmission of resistant HCV. Given the considerable cost
of these treatments, resources invested in optimizing the
psychosocial readiness of patients prior to treatment initiation
and providing on-treatment adherence support may prove
cost-effective. These assessment and intervention strategies
should be evaluated through research which includes a cost-
effectiveness component.ing TID regimens using electronic monitoring.
s on TID Dose Adherence 
Mean % (SD)
TID Dose Interval Adherence
Mean % (SD)
66 (29) 46 (31)
85.7a 45a
80 (18) 40 (19)
65.8 (30.1) 5.3 (5.3)
88.9 (13.9) 52.6 (27.7)
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Herbal medicine hepatotoxicity revisited
To the Editor:
In the April 2011 issue of the Journal of Hepatology, an editorial
discussed hepatotoxicity associated with the use of herbal prep-
arations [1]. The focus of the article is primarily on the need to
develop speciﬁc biomarkers for compounds or ingredients sus-
pected to be associated with hepatotoxicity in order to establish
clinical speciﬁcity when determining if a relationship exists
between an adverse event and the consumption of these agents.
We agree that identiﬁcation methods are crucial to product
safety and the industry continues to develop and validate identi-
ﬁcation methods for many commercialized ingredients. This issue
is also currently being addressed by the US Food and Drug
Administration (FDA) and various other regulatory agencies
worldwide. In the US, beginning in 2008, the FDA has enforced
the formal requirement for dietary supplement manufacturers
to comply with dietary supplement-speciﬁc Current Good Manu-
facturing Practices (cGMP) [2]. The regulations outline the
requirements that support product quality and safety including
ingredient testing, manufacturing equipment and facilities, man-
ufacturing process controls, product testing, product complaint
handling, and documentation. It is important to appreciate how
this higher level of scrutiny for dietary supplements allows for
better assurance against potential safety issues, including issues
related to contamination, adulteration, distribution, and safety
monitoring. It would be equally prudent to acknowledge that
since 2008, these manufacturing controls could mitigate ingredi-
ent contamination concerns that were suggested as the proposed
mechanisms involved with cases of liver injury associated with
these products. This article gives several examples of speciﬁc
ingredients alleged to have been associated with cases of liver
injury including references to Herbalife which is a brand, not a
single product or ingredient. The reference to Herbalife is also
somewhat immaterial in the context of the article’s discussion.
Herbalife has formally responded to this publication [3] to rebut
articles cited by these authors [4,5]. The articles were published
in 2007 and present case reports with dates of onset that range
from 1998 to 2004. These case reports involved a variety of food
and supplement products that are not representative of currently
marketed Herbalife products. Additionally, no toxic substance has
been identiﬁed as responsible for the liver reactions that were
alleged to have been associated with Herbalife products and none
of the suspect compounds listed by these authors are found in
any of Herbalife’s products. Although Herbalife uses green tea
extracts in its current products, all green tea extracts are water-
based extracts (equivalent to a hot tea infusion) that have never
been implicated in causing liver toxicity. Furthermore, since
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